Update on rheumatic heart disease

Current Opinion in Cardiology

Volumn 31, Issue 2, 2016, Pages 162-168

  Yanagawa, Bobby ^a   Butany, Jagdish ^b   Verma, Subodh ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

autoimmune; mitral stenosis; rheumatic heart disease

Indexed keywords

AUTOANTIGEN; MYOSIN; STREPTOCOCCUS ANTIGEN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; AUTOIMMUNITY; ECHOCARDIOGRAPHY; ENDOTHELIUM INJURY; GENETICS; HEART VALVE REPLACEMENT; HUMAN; INNATE IMMUNITY; MOLECULAR MIMICRY; PATHOGENESIS; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SARCOMERE; TRANSLUMINAL VALVULOPLASTY; VALVULOPLASTY; ADVERSE EFFECTS; DISEASE MANAGEMENT; HEART SURGERY; IMMUNITY; IMMUNOLOGY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; CARDIAC SURGICAL PROCEDURES; DISEASE MANAGEMENT; ECHOCARDIOGRAPHY; HUMANS; IMMUNITY; MOLECULAR MIMICRY; OUTCOME ASSESSMENT (HEALTH CARE); RHEUMATIC HEART DISEASE;

EID: 84957597756     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000269     Document Type: Review

References (73)

1. Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation 2015; 131:1806-1818.
2. Narula J, Chopra P, Talwar KK, et al. Does endomyocardial biopsy aid in the diagnosis of active rheumatic carditis? Circulation 1993; 88:2198-2205.
3. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685-694.
4. Carapetis JR, Hardy M, Fakakovikaetau T, et al. Evaluation of a screening protocol using auscultation and portable echocardiography to detect asymptomatic rheumatic heart disease in Tongan schoolchildren. Nat Clin Pract Cardiovasc Med 2008; 5:411-417.
5. Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007; 357:470-476.
6. Gunther G, Asmera J, Parry E. Death from rheumatic heart disease in rural Ethiopia. Lancet 2006; 367:391.
7. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987; 316:421-427.
8. Gupta M, Lent RW, Kaplan EL, et al. Serum cardiac troponin I in acute rheumatic fever. Am J Cardiol 2002; 89:779-782.
9. Roberts WC, Virmani R. Aschoff bodies at necropsy in valvular heart disease. Evidence from an analysis of 543 patients over 14 years of age that rheumatic heart disease, at least anatomically, is a disease of the mitral valve. Circulation 1978; 57:803-807.
10. Rajamannan NM, Nealis TB, Subramaniam M, et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 2005; 111:3296-3301.
11. van Kempen TS, Wenink MH, Leijten EF, et al. Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol 2015; 11:483-492.
12. Park H, Bourla AB, Kastner DL, et al. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 2012; 12:570-580.
13. Chiu-Braga YY, Hayashi SY, Schafranski M, et al. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). Int J Cardiol 2006; 109:275-276.
14. Gölbasi Z, Uçar O, Keles T, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail 2002; 4:593-595.
15. Guilherme L, Cury P, Demarchi LM, et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol 2004; 165:1583-1591.
16. Yetkin E, Erbay AR, Ileri M, et al. Levels of circulating adhesion molecules in rheumatic mitral stenosis. Am J Cardiol 2001; 88:1209-1211.
17. Alyan O, Metin F, Kacmaz F, et al. High levels of high sensitivity C-reactive protein predict the progression of chronic rheumatic mitral stenosis. J Thromb Thrombolysis 2009; 28:63-69.
18. Davutoglu V, Celik A, Aksoy M. Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J Heart Valve Dis 2005; 14:251-256.
19. Chen MC, Wu CJ, Yip HK, et al. Increased circulating endothelin-1 in rheumatic mitral stenosis: irrelevance to left atrial and pulmonary artery pressures. Chest 2004; 125:390-396.
20. Galvin JE, Hemric ME, Ward K, et al. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest 2000; 106:217-224.
21. Scalzi V, Hadi HA, Alessandri C, et al. Antiendothelial cell antibodies in rheumatic heart disease. Clin Exp Immunol 2010; 161:570-575.
22. Roberts S, Kosanke S, Terrence Dunn S, et al. Pathogenic mechanisms in rheumatic carditis: focus on valvular endothelium. J Infect Dis 2001; 183:507-511.
23. Schafranski MD, Pereira FL, Scherner D, et al. High-producing MBL2 genotypes increase the risk of acute and chronic carditis in patients with history of rheumatic fever. Mol Immunol 2008; 45:3827-3831.
24. Kaplan MH, Bolande R, Ratika L, et al. Presence of bound immunoglobulins and complement in the myocardium in acute rheumatic fever. N Engl J Med 1964; 271:637.
25. Quinn A, Kosanke S, Fischetti VA, et al. Induction of autoimmune valvular heart disease by recombinant streptococcal M protein. Infect Immun 2001; 69:4072-4078.
26. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: Cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol 2010; 30:17-23.
27. Guilherme L, Dulphy N, Douay C, et al. Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. Int Immunol 2000; 12:1063-1074.
28. Ellis NM, Li Y, Hildebrand W, et al. T cell mimicry and epitope specificity of cross-reactive T cell clones from rheumatic heart disease. J Immunol 2005; 175:5448-5456.
29. Faé KC, da Silva DD, Oshiro SE, et al. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol 2006; 176:5662-5670.
30. Delunardo F, Scalzi V, Capozzi A, et al. Streptococcal-vimentin cross-reactive antibodies induce microvascular cardiac endothelial proinflammatory phenotype in rheumatic heart disease. Clin Exp Immunol 2013; 173:419-429.
31. Fischetti VA. Streptococcal M protein. Sci Am 1991; 264:58-65.
32. Goldstein I, Rebeyrotte P, Parlebas J, et al. Isolation from heart valves of glycopeptides which share immunological properties with Streptococcus haemolyticus group A polysaccharides. Nature 1968; 219:866-868.
33. Dudding BA, Ayoub EM. Persistence of streptococcal group A antibody in patients with rheumatic valvular disease. J Exp Med 1968; 128:1081-1098.
34. Ayoub EM, Taranta A, Bartley TD. Effect of valvular surgery on antibody to the group A streptococcal carbohydrate. Circulation 1974; 50:144-150.
35. Tandon R, Sharma M, Chandrashekhar Y, et al. Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol 2013; 10:171-177.
36. Dinkla K, Rohde M, Jansen WT, et al. Rheumatic fever-associated Streptococcus pyogenes isolates aggregate collagen. J Clin Invest 2003; 111:1905-1912.
37. Dinkla K, Nitsche-Schmitz DP, Barroso V, et al. Identification of a streptococcal octapeptide motif involved in acute rheumatic fever. J Biol Chem 2007; 282:18686-18693.
38. Dinkla K, Talay SR, Mörgelin M, et al. Crucial role of the CB3-region of collagen IV in PARF-induced acute rheumatic fever. PLoS One 2009; 4:e4666.
39. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014; 343:152-157.
40. Wilson MG, Schweitzer MD. Pattern of hereditary susceptibility in rheumatic fever. Circulation 1954; 10:699-704.
41. Uchida IA. Possible genetic factors in the etiology of rheumatic fever. Am J Hum Genet 1953; 5:61-69.
42. Engel ME, Stander R, Vogel J, et al. Genetic susceptibility to acute rheumatic fever: a systematic review and meta-analysis of twin studies. PLoS One 2011; 6:e25326.
43. Guédez Y, Kotby A, El-Demellawy M, et al. HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Circulation 1999; 99:2784-2790.
44. Carlquist JF, Ward RH, Meyer KJ, et al. Immune response factors in rheumatic heart disease: meta-analysis of HLA-DR associations and evaluation of additional class II alleles. J Am Coll Cardiol 1995; 26:452-457.
45. Berdeli A, Celik HA, Ozyürek R, et al. TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med 2005; 83:535-541.
46. Settin A, Abdel-Hady H, El-Baz R, et al. Gene polymorphisms of TNF-alpha(- 308), IL-10(-1082), IL-6(-174), and IL-1Ra(VNTR) related to susceptibility and severity of rheumatic heart disease. Pediatr Cardiol 2007; 28:363-371.
47. Chou HT, Chen CH, Tsai CH, et al. Association between transforming growth factor-beta1 gene C-509T and T869C polymorphisms and rheumatic heart disease. Am Heart J 2004; 148:181-186.
48. Azevedo PM, Bauer R, Caparbo Vde F, et al. Interleukin-1 receptor antagonist gene (IL1RN) polymorphism possibly associated to severity of rheumatic carditis in a Brazilian cohort. Cytokine 2010; 49:109-113.
49. Kamal H, Hussein G, Hassoba H, et al. Transforming growth factor-beta1 gene C-509T and T869C polymorphisms as possible risk factors in rheumatic heart disease in Egypt. Acta Cardiol 2010; 65:177-183.
50. Messias-Reason IJ, Schafranski MD, Kremsner PG, et al. Ficolin 2 (FCN2) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease. Clin Exp Immunol 2009; 157:395-399.
51. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipidlowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352:2389-2397.
52. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343-1356.
53. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49:554-561.
54. Antonini-Canterin F, Leiballi E, Enache R, et al. Hydroxymethylglutaryl coenzyme- a reductase inhibitors delay the progression of rheumatic aortic valve stenosis a long-term echocardiographic study. J Am Coll Cardiol 2009; 53:1874-1879.
55. Antonini-Canterin F, Moura LM, Enache R, et al. Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease. Circulation 2010; 121:2130-2136.
56. Devaraj S, Rogers J, Jialal I. Statins and biomarkers of inflammation. Curr Atheroscler Rep 2007; 9:33-41.
57. Voss LM, Wilson NJ, Neutze JM, et al. Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial. Circulation 2001; 103:401-406.
58. Cilliers A, Manyemba J, Adler AJ, et al. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev 2012; 6:CD003176.
59. Hung JS, Chern MS, Wu JJ, et al. Short- and long-term results of catheter balloon percutaneous transvenous mitral commissurotomy. Am J Cardiol 1991; 67:854-862.
60. Song JK, Kim MJ, Yun SC, et al. Long-term outcomes of percutaneous mitral balloon valvuloplasty versus open cardiac surgery. J Thorac Cardiovasc Surg 2010; 139:103-110.
61. Gao C, Yang M, Xiao C, et al. Robotically assisted mitral valve replacement. J Thorac Cardiovasc Surg 2012; 143:S64-S67.
62. Holzhey DM, Shi W, Borger MA, et al. Minimally invasive versus sternotomy approach for mitral valve surgery in patients greater than 70 years old: a propensity-matched comparison. Ann Thorac Surg 2011; 91:401-405.
63. Kim JB, Kim HJ, Moon DH, et al. Long-term outcomes after surgery for rheumatic mitral valve disease: valve repair versus mechanical valve replacement. Eur J Cardiothorac Surg 2010; 37:1039-1046.
64. De Santo LS, Romano G, Della Corte A, et al. Mitral mechanical replacement in young rheumatic women: analysis of long-term survival, valve-related complications, and pregnancy outcomes over a 3707-patient-year followup. J Thorac Cardiovasc Surg 2005; 130:13-19.
65. Remenyi B, Webb R, Gentles T, et al. Improved long-term survival for rheumatic mitral valve repair compared to replacement in the young. World J Pediatr Congenit Heart Surg 2013; 4:155-164.
66. Gometza B, Al-Halees Z, Shahid M, et al. Surgery for rheumatic mitral regurgitation in patients below twenty years of age: an analysis of failures. J Heart Valve Dis 1996; 5:294-301.
67. Kalangos A, Christenson JT, Beghetti M, et al. Mitral valve repair for rheumatic valve disease in children: midterm results and impact of the use of a biodegradable mitral ring. Ann Thorac Surg 2008; 86:161-168.
68. Yakub MA, Krishna Moorthy PS, Sivalingam S, et al. Contemporary long-term outcomes of an aggressive approach to mitral valve repair in children: is it effective and durable for both congenital and acquired mitral valve lesions? Eur J Cardiothorac Surg 2015. [Epub ahead of print]
69. Yau TM, El-Ghoneimi YA, Armstrong S, et al. Mitral valve repair and replacement for rheumatic disease. J Thorac Cardiovasc Surg 2000; 119:53-60.
70. Dillon J, Yakub MA, Kong PK, et al. Comparative long-term results of mitral valve repair in adults with chronic rheumatic disease and degenerative disease: is repair for 'burnt-out' rheumatic disease still inferior to repair for degenerative disease in the current era? J Thorac Cardiovasc Surg 2015; 149:771-777.
71. Waikittipong S. Mitral valve repair for rheumatic mitral regurgitation: Mid-term results. Asian Cardiovasc Thorac Ann 2015; 23:658-664.
72. Thomas MP, Badhwar V. A three-step technique for repair of rheumatic disease of the mitral valve. Cardiol Young 2014; 24:1104-1107.
73. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2438-2488